Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Emerging directions in tauopathy research.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Social vulnerability shapes deep clinical phenotypes and brain health in aging and dementia across Latin America.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Genetic-exposome interactions and aging clocks in dementia: the ReDLat2 initiative.

Nature medicine·2026
Same author

Multilevel Impact of Parental Burnout on Mothers and Preschool Children.

Chronic stress (Thousand Oaks, Calif.)·2026
Same author

Neural embedding of frailty in cognitively unimpaired aging and dementia across Latin America.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Contextualizing Blood-Based Biomarkers for Dementia Globally.

Journal of neurochemistry·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Claudia Duran-Aniotz1

  • 1Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibañez, Santiago, Chile.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

针对阿尔茨海默病 (AD) 和前叶退行症 (FTLD) 的等离子体生物标志物显示出全球效用. 将这些生物标志物与神经成像相结合,可以提高不同拉丁美洲人口中痴呆症诊断的准确性.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物 生物标志物
  • 神经退行性疾病 神经退行性疾病

背景情况:

  • 血生物标志物对于痴呆症诊断至关重要,但需要在不同人群中进行验证.
  • 在拉丁美洲 (LA),对阿尔茨海默病 (AD) 和前叶退化 (FTLD) 生物标志物的评估有限.

研究的目的:

  • 在多国多样化的LA队列中评估血生物标志物 (Aβ40,Aβ42,Aβ42/Aβ40,p-tau181,NfL).
  • 评估这些AD和FTLD生物标志物的诊断准确性.
  • 探索生物标志物与神经成像的整合,以改善痴呆症诊断.

主要方法:

  • 在五个LA国家招募了637名参与者.
  • 测量了血中的Aβ40,Aβ42,p-tau181和NfL水平.
  • 使用回归,机器学习 (ML) 和神经成像.

主要成果:

  • 在AD和FTLD下降的Aβ42/Aβ40比率表明了粉样蛋白病理.
  • 在AD/FTLD中增加的p-tau181和在FTLD中增加的NfL表明tau病理和神经退行.
  • 使用AT(N) 生物标志物的ML模型实现了高诊断准确度 (AD=83%,FTLD=88%).
  • 与神经成像的整合进一步提高了准确性 (AD=88%,FTLD=89%).

结论:

  • 血AT(N) 生物标志物显示出对痴呆症诊断的全球实用性.
  • 与临床和神经解剖学评估的整合提高了不同人群的诊断性能.
  • 这些发现支持使用血生物标志物来改善拉丁美洲的痴呆症检测.